Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib

Learn more about:
Related Clinical Trial
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS Comparison of Robotic Arm-assisted PET/CT-guided Lung Biopsy With PET Fused CT- Fluoroscopy-guided Lung Biopsy ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib Comparative Genomic Profiling of Lung Adenocarcinoma in Asians and Caucasians: A Propensity Matched Analysis Therapeutic ResistAnce and Clonal Evolution of ICIs Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Icotinib for Completed Resected IB NSCLC With EGFR Mutation Circulating Tumor DNA in Patients at High Risk for Lung Cancer Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery QUILT-3.017: Study of NEO-201 in Solid Tumors Photodynamic Therapy in Treating Patients With Lung Cancer Vaccine Treatment for Advanced Non-Small Cell Lung Cancer S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC The Tracking Molecular Evolution for NSCLC (T-MENC) Study Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) P2 of RMT in Combo w Durvalumab or Durva + Chemo in Untreated Adenocarcinoma NSCLC Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma Prospective Radiological Study of HRCT to Predict Pathological Noninvasiveness in NSCLC To Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001) Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung Lung Cancer Mutation Consortium Protocol The Detection of EGFR Mutations in Liquid Based Cytology Samples NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03) Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR Telomere Biology in Early Adenocarcinoma of the Lung

Brief Title

Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib

Official Title

Safety and Efficacy of Osimertinib Combined With Anlotinib in EGFRm+, Treatment-naïve IIIb/IV NSCLC Patients: a Prospective, Single Arm, Phase Ib/IIa Study

Brief Summary

      This is a prospective, single arm, phase Ib/IIa study. Up to 25 patients will be enrolled
      into the study (Part A: 2-18; Part B: 7-19). The study has been designed to allow an
      investigation of the optimal combination dose and schedule whilst of Osimertinib plus
      Anlotinib in patients with EGFRm+, treatment-naïve IIIb/IV Non-Small Cell Lung Cancer (NSCLC)
      ensuring the safety of patients with intensive safety monitoring. There are two main parts to
      this study; Part A, Combination dose finding and Parts B, Dose expansion.

Detailed Description

      Part A has been designed to identify the recommended dose of the combination of Osimertinib
      plus Anlotinib for further clinical evaluation based upon assessment of the safety and
      tolerability data collected during the first 21 days (cycle 1, 21 days per cycle). A cycle of
      study treatment will be defined as 21 days. Dosing will begin at Osimertinib 80mg QD
      continuously and Anlotinib 8mg QD from day1 to 14 of a 21-day cycle. In the first 6 patients,
      a delay of at least 21 days (the first group of 3 patients) and a delay of at least 7 days
      (the second group of 3 patients) will be mandatory between the administration of the first
      dose to the first patient and administration of first dose to subsequent patients. Patients
      will be enrolled to ensure a minimum of 3 and a maximum of 6 evaluable patients per cohort.
      Dose escalation and de-escalation will follow the scheme below, according to the following
      logic:If no dose-limiting toxicity (DLT) is observed (for definition see Section 4.1.3) in a
      cohort of 3 evaluable patients then dose escalation may occur. Dose increases will be
      permitted after review of data from a minimum of 3 evaluable patients has been performed.

        -  If one patient experiences a DLT in a group of 3 evaluable patients then the cohort will
           be expanded to include 6 evaluable patients. If only one DLT is observed in the complete
           cohort of 6 evaluable patients then dose escalation may occur.

        -  If 2 or more patients experience a DLT in a group of up to 6 patients, irrespective of
           the number of patients enrolled, the dose will be considered not tolerated and
           recruitment to the cohort and dose escalation will cease.

      Safety will be intensively monitored in part A. If RP2D was not reached in Part A, Part B
      would not be initiated. If RP2D was reached in Part A, eligible patients in part B will be
      enrolled and receive Osimertinib (80mg QD, continuously) plus Anlotinib (RP2D, QD from day 1
      to 14 of a 21-day cycle) till disease progression (PD) or unacceptable toxicity, with the aim
      to further evaluate the safety, tolerability and efficacy in terms of ORR, DCR, DOR, PFS,
      overall survival at 12 months.

      For all eligible patients (Part A and Part B), tissue and/or blood samples at baseline and PD
      will be collected to understand the resistance profile.

Study Phase

Phase 1/Phase 2

Study Type


Primary Outcome

Recommended Phase II Dose(RP2D)

Secondary Outcome

 Dose-limiting toxicity (DLT)


Non-Small Cell Lung Cancer With EGFR Mutation



Study Arms / Comparison Groups

 Osimertinib + Anlotiib
Description:  Escalating doses and expanding doses of Anlotinib administered with Osimertinib


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

November 19, 2020

Completion Date

November 30, 2025

Primary Completion Date

November 30, 2022

Eligibility Criteria

        Inclusion Criteria:

          -  For inclusion in the study subjects should fulfil the following criteria:

               1. Provision of informed consent prior to any study specific procedures.

               2. Aged at least 18 years.

               3. Histologically or cytologically confirmed locally advanced/metastasis NSCLC,
                  adenocarcinoma of the lung (AJCC Eighth Edition TNM Stage ⅢB to stage Ⅳ), not
                  amenable to curative surgery or radiotherapy.

               4. WHO/Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1 with no
                  deterioration over the previous 2 weeks and a minimum life expectation of at
                  least 12 weeks.

               5. The tumour harbours one of the most common EGFR mutations known to be associated
                  with EGFR-TKI sensitivity (exon 19 deletion; L858R) either alone or in
                  combination with other EGFR mutations as confirmed by a local test.

               6. No prior systemic anti-cancer, EGFR-TKI, or immunotherapy therapy for their
                  locally advanced or metastasis disease (biopsy will be at time of diagnosis of
                  locally advanced/metastasis disease).

               7. At least one lesion is measurable based on Response Evaluation Criteria in Solid
                  Tumours (RECIST 1.1).

               8. Adequate bone marrow reserve and organ function as follows:

          -  Absolute neutrophils count (ANC) ≥1.5x109/L (band neutrophil and segmented
             neutrophil), platelets >100x109/L and Hb ≥90g/L.

          -  Hepatic: total bilirubin ≤1.5 times upper limit of normal (ULN).

          -  Alkaline phosphatase, alanine transaminase (ALT) and aspartate transaminase (AST)≤3.0
             ULN (or ≤5 ULN in case of known liver involvement).

          -  Renal: Serum Creatinine ≤1.5ULN, creatinine clearance (CCr) ≥50mL/min 9. Female
             patients of childbearing potential must be using adequate contraceptive measures (see
             Restrictions, Section3.5), must not be breast feeding, and must have a negative
             pregnancy test prior of study treatments and confirmed prior to start of dosing on day
             1. Otherwise, they must have evidence of non-childbearing potential as defined below:

          -  Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12
             months following cessation of all exogenous hormonal treatments

          -  Women under 50 years would be consider post-menopausal if they have been amenorrheic
             for 12 months or more following cessation of exogenous hormonal treatments and with
             luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal
             range for the institution

          -  Documentation of irreversible surgical sterilisation by hysterectomy, bilateral
             oophorectomy or bilateral salpingectomy but not tubal ligation 10. Male patients must
             be willing to use barrier contraception, i.e., condoms (see Restrictions, Section 3.5)
             11. Optional provision of an unstained, archived tumour tissue samples or fresh tissue
             and/or blood in a quantity sufficient to allow for central NGS testing (FFPE slices or
             fresh tumor tissue or blood at sufficient amount for NGS analysis).

        Exclusion Criteria:

        - Subjects must not enter the study if any of the following exclusion criteria are

          1. Patients with non-lung adenocarcinoma including lung squamous carcinoma, or mixed
             histology, etc.

          2. Treatment with any of the following:

               -  Major surgery (excluding placement of vascular access) within 4 weeks of the
                  first dose of study drug.

               -  Patients currently receiving (or unable to stop use prior to receiving the first
                  dose of study drug) medications or herbal supplements known to be potent inducers
                  of CYP3A4 (at least 3-week prior) (Appendix B). All patients must try to avoid
                  concomitant use of any medications, herbal supplements and/or ingestion of foods
                  with known inducer effects on CYP3A4.

               -  Treatment with an investigational drug within five half-lives of the compound or
                  3 months, whichever is greater.

          3. Any concurrent and/or other active malignancy that has required treatment within 5
             years of first dose of study drug.

          4. Any unresolved toxicities from prior systemic therapy (e.g., adjuvant chemotherapy)
             greater than CTCAE grade 1 at the time of starting study drug with the exception of
             alopecia and grade 2, prior chemotherapy-induced neuropathy.

          5. Spinal cord compression, symptomatic and unstable brain metastases, except for those
             patients who have completed definitive therapy, and have had a stable neurological
             status for at least 2 weeks after completion of definitive therapy. Patients may be on
             corticosteroids to control brain metastases if they have been on a stable dose for 2
             weeks (14 days) prior to the start of study treatment and are clinically asymptomatic.

          6. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled
             hypertension and active bleeding diatheses, which in the investigator's opinion makes
             it undesirable for the patient to participate in the trial or which would jeopardise
             compliance with the protocol, or active infection including hepatitis B, hepatitis C
             and human immunodeficiency virus (HIV). Screening for chronic conditions is not

          7. Recent active digestive disease such as duodenal ulcers, ulcerative colitis, ileus,
             ect., intestinal perforation, intestine fistula, or other conditions may lead to
             gastrointestinal bleeding or perforation which regimented at investigators'

          8. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to
             swallow the formulated product, or previous significant bowel resection that would
             preclude adequate absorption of Osimertinib and Anlotinib.

          9. Cardiac function evaluation: LVEF <50%, a recent history of MI in 6 months,
             severe/unstable angina or coronary bypass surgery, or cardiac insufficiency ≥ NYHA 2.
             Any of the following cardiac criteria:

               -  Mean resting corrected QT interval (QTc) >470 msec.

               -  Any clinically important abnormalities in rhythm, conduction, or morphology of
                  resting ECG, e.g., complete left bundle branch block, third-degree heart block,
                  second-degree heart block, interval >250 msec.

               -  Any factors that increase the risk of QTc prolongation or risk of arrhythmic
                  events such as heart failure, electrolyte abnormalities (including: Serum/plasma
                  potassium < LLN; Serum/plasma magnesium < LLN; Serum/plasma calcium < LLN),
                  congenital long QT syndrome, family history of long QT syndrome, or unexplained
                  sudden death under 40 years of age in first-degree relatives or any concomitant
                  medication known to prolong the QT interval and cause Torsades de Pointes.

               -  Past medical history of ILD, drug-induced ILD, radiation pneumonitis which
                  require steroid treatment, or any evidence of clinically active ILD.

               -  Previous allogenic bone marrow transplant.

               -  Pregnant or lactating woman who are breast feeding.

               -  A history of organ transplantation and long-term immunosuppressive medication.

               -  History of hypersensitivity to active or inactive of Osimertinib or Anlotinib or
                  drugs with a similar chemical structure or class to osimertinib or Anlotinib.

         10. Judgment by the Investigator that the patients should not participate in the study if
             the patient is unlikely to comply with study procedures, restrictions, and
             requirements.; or other conditions regimented at investigators' discretion.




18 Years - N/A

Accepts Healthy Volunteers



, 13817833343, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

Shanghai Chest Hospital

Study Sponsor

, , 

Verification Date

February 2021